"Secured patents in Australia, Canada, Japan and New Zealand to one of their New Chemical Entity (NCE) for CNS therapy through new mechanism of action – H3 Inverse agonist," the company said in a BSE filing.
    
These patents are valid until 2030, it added.
    
Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.
    
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are useful in treatment of cognitive impairment associated with neurodegenerative disorders, the statement said.
    
Commenting on the development, Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and huge market potential globally."
    
With these new patents, Suven has 20 granted patents from Australia, 17 granted patents from Canada, 15 granted patents from Japan and 22 granted patents from New Zealand.
    
"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts.
    
"Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," the statement added.

Latest News  from Business News Desk